Pharmacotherapeutic options for hepatitis B. - Wikidata - awgldk - TriplyDB

Pharmacotherapeutic options for hepatitis B.

Pharmacotherapeutic options for hepatitis B.

http://www.wikidata.org/entity/Q38631076

about

A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway.

P2860

Q47105994-B7BEA9D7-AF04-4858-B08D-7554312930F7

P2860

Pharmacotherapeutic options for hepatitis B.

http://www.wikidata.org/entity/Q38631076

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacotherapeutic options for hepatitis B.

@en

type

label

Pharmacotherapeutic options for hepatitis B.

@en

prefLabel

Pharmacotherapeutic options for hepatitis B.

@en

P1433

Q38631076-FF04C98D-BEE4-4224-960B-5339D7D7EAF5

P1476

Q38631076-77D62422-74D0-4BF8-B7CC-1D5CEF0B9D60

P2093

Q38631076-C2D8AB40-7C26-4159-824C-C17BAD720CF3

P2860

Q38631076-05D4EA0B-92E1-4374-AFEF-20640C20E9CE

Q38631076-070B9089-399B-47E9-8B9D-E61E7AABD2E5

Q38631076-080A23BF-784C-4633-A181-BA0922D44E5D

Q38631076-0872D664-DF1C-4C30-A5E0-F84AE79909F7

Q38631076-08758D01-7DE9-494A-AD86-FD6C319CFC0C

Q38631076-0BC9FA32-9334-494B-9635-5142FA4B415F

Q38631076-0C611680-67B5-46C7-8BE8-43010D04B8F1

Q38631076-0D0166A8-994B-441F-9896-7A5AC9ADDD5A

Q38631076-1324ABAA-E90E-4906-94D7-0D578B0D50F9

Q38631076-13ED1DF2-7BB1-4A2B-96CD-989F86BEF6A5

P304

Q38631076-2516CD96-1A5F-4B9A-B0A1-3BE21AC7577D

P31

Q38631076-EE431D6B-85A5-4523-A158-11EDC8132F47

P356

Q38631076-8990F7A8-9C83-409A-8B80-E34E43813A1F

P407

Q38631076-1AFFB6AE-BB15-4CFA-8012-F7D6AD3B1DF2

P433

Q38631076-328D2103-DB28-4EC5-8790-1A6073D5A6A0

P478

Q38631076-A202AF95-40AF-416B-9467-E6CC196F9C24

P50

Q38631076-1eeb2835-416c-bd68-4c4c-216b2eefbe41

P577

Q38631076-8000829A-4DD9-4ACF-AD88-99B755350570

P698

Q38631076-F5D6D4DF-2DDB-450B-8496-877D15839B9B

P356

14656566.2016.1118056

P1433

Expert Opinion on Pharmacotherapy

P1476

Pharmacotherapeutic options for hepatitis B.

@en

P2093

Yi-Cheng Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Management of patients with hepatitis B who require immunosuppressive therapy

Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

Telbivudine versus lamivudine in patients with chronic hepatitis B

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

P304

355-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2016.1118056

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26559942

http://www.w3.org/2001/XMLSchema#string